Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	377111	COMIRNATY (tozinameran) COVID-19 VACCINE 10 micrograms/0.2 mL concentrated suspension for injection vial

ARTG entry for	Medicine Registered (Provisional)
Sponsor	Pfizer Australia Pty Ltd
Postal Address	GPO Box 7015, Sydney, NSW, 2001 Australia
ARTG Start Date	6/12/2021
Product Category	Medicine
Status	Active
Approval Area	Drug Safety Evaluation Branch

Medicine under additional monitoring

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 11.

Except where the sponsor has been contracted by an overseas partry to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

Products

1 . COMIRNATY (tozinameran) COVID-19 VACCINE 10 micrograms/0.2 mL concentrated suspension for injection vial

Product Type	Single Medicine Product	**Effective Date**	22/05/2023

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Provisionally Registered Indications

COMIRNATY (tozinameran) COVID-19 Vaccine has provisional approval for the indication below:,Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 5 years of age to less than 12 years of age.,The use of this vaccine should be in accordance with official recommendations.,The decision has been made on the basis of short term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

Provisionally Registered Conditions

Provisional registration to extend the indication to individuals 6 months - <5 years, register a new strength and make other amendments to the PI with conditions as specified in the letter dated 29 September 2022 from CESA PMAB advising of approval for the registration of the goods (PM-2022-03129-1-2) D22-5937435

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

This product is included in the Black Triangle Scheme

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Glass Type I Clear	18 Months	Store between minus 60 - minus 90 degrees	Neither child resistant closure nor restricted flow insert	Protect from Light

Pack Size/Poison information

Pack Size	Poison Schedule
195 vials	(S4) Prescription Only Medicine
10	(S4) Prescription Only Medicine

Components

1 . COMIRNATY (tozinameran [mRNA]) COVID-19 VACCINE 10 micrograms/0.2 mL concentrated suspension for injection vial

Dosage Form	Injection, concentrated
Route of Administration	Intramuscular
Visual Identification	White to off-white frozen liquid.

Active Ingredients

tozinameran	**130 microgram**

Other Ingredients (Excipients)

((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
2-((polyethylene glycol)-2000)-N-N-ditetradecylacetamide
cholesterol
distearoylphosphatidylcholine
sucrose
trometamol hydrochloride
trometamol
water for injections

Public Summary

Public Summary